Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

• المؤلفون الرئيسيون: Xiaomin Wan (مؤلف), Xiaohui Zeng (مؤلف), Liubao Peng (مؤلف), Ye Peng (مؤلف), Qiao Liu (مؤلف), Lidan Yi (مؤلف), Xia Luo (مؤلف), Qijian Deng (مؤلف), Chongqing Tan (مؤلف)
• التنسيق: كتاب
• منشور في: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Objective: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab vs. chemotherapy in the first-line setting for patients with advanced non-small-cell lung cancer (NSCLC) from the US payer perspective.Materials and methods: A Markov model wasdeveloped to evaluate the cost and effec...